Reduced Healthcare Resource Utilization (HCRU) with Pritelivir Compared to Investigator's Choice Therapy (ICT) in Immunocompromised (IC) Patients Treated for Refractory Herpes Simplex Virus (HSV): Phase 3 PRIOH-1 Study (IDWeek 2026) - Sep 6, 2026 - Abstract #P - 28; Pres time: Oct 22, 2026; 12:15 PM - 01:30 PM; Location: Poster Hall B-C; No abstract available
Clinical • HEOR • P3 data • Herpes Simplex • Infectious Disease
|
|
Ryan C. Maves, MD (he/him/his); Robin K. Avery, MD, FIDSA; Karl Peggs, MD; Anum Abbas, MD; Jana K. Dickter, MD (she/her/hers); Sanjeet S. Dadwal, MD (he/him/his); Stuart Cohen, MD; Genovefa Papanicolaou, MD; Yeon Joo Lee, MD, MPH; Roy F. Chemaly, MD/MPH (he/him/his); Dionysios Neofytos, MD; Jean-Michel Molina, MD; PhD; Palash Samanta, MD (he/him/his); Dilruwan C Herath, MD; Cynthia Wat, MBBS MRCP MFPM; Melanie E. Sumner, MSc; Alessandra Marini, MD; Kirthana Beaulac, PharmD; Kimberly Workowski, MD
|